Tegaserod

ApprovedTerminated

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Gastroparesis

Conditions

Gastroparesis, Diabetes

Trial Timeline

Jan 1, 2007 → Mar 1, 2007

NCT ID

NCT00390975

About Tegaserod

Tegaserod is a approved stage product being developed by Novartis for Gastroparesis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00390975. Target conditions include Gastroparesis, Diabetes.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

19 competing products in Gastroparesis

See all competitors

Product	Company	Stage	Hype Score
tadalafil + tadalafil + placebo	Eli Lilly	Phase 2	52
Granisetron	Kyowa Kirin	Phase 2	52
tadalafil	Eli Lilly	Approved	85
Mosapride + domperidone	Sumitomo Pharma	Approved	85
Cisapride + Placebo	Johnson & Johnson	Approved	85
Cisapride + Placebo	Johnson & Johnson	Approved	85
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet	AstraZeneca	Phase 2	52
Sitagliptin + Placebo	Merck	Phase 1	33
Reglan ODT	UCB	Pre-clinical	20
Hemin + Albumin	Recordati	Phase 2	49
CNSA-001 + Placebo	PTC Therapeutics	Phase 2	49
Immediate-release omeprazole + Delayed-release omeprazole	Bausch Health	Approved	80
Velusetrag + Placebo	Theravance Biopharma	Phase 2	47
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo	Theravance Biopharma	Phase 2	47
IW-9179 + Matching Placebo	Ironwood Pharmaceuticals	Phase 2	44
VLY-686 (Tradipitant)	Vanda Pharmaceuticals	Phase 2	44
Tradipitant	Vanda Pharmaceuticals	Phase 3	69
Tradipitant	Vanda Pharmaceuticals	Pre-clinical	15
Tradipitant + Placebo + Open Label Tradipitant	Vanda Pharmaceuticals	Phase 3	69

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved